Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare Hereditary Metabolic Diseases

 Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare Hereditary Metabolic Diseases

Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare Hereditary Metabolic Diseases

 Shots:

  • The collaboration is a focus of combining Evotec’s stem cell (“iPSC”) platform with Immuneering’s Artificial Intelligence drug discovery platform for development of therapies
  • Additionally, Immuneering’s AI platform fluency will assist in analyzing public and proprietary data, for identification of novel candidates
  • AI platform is a drug discovery based technology used to discover & develop single and multi-targeted drugs with molecular-level data

Click here to read full press release/ article | Ref: Evotec | Image: The Pharma Letter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post